Description
Is Briganix 180 mg right for your situation?
Review these criteria with your oncologist before enquiring- ✓Confirmed ALK-positive metastatic NSCLC on molecular testing
- ✓Progressed on or intolerant to a prior ALK inhibitor (e.g. crizotinib)
- ✓Need an affordable WHO-GMP generic alternative to Alunbrig® (Takeda)
- ✓Hold a valid oncologist prescription
- ✗ALK-negative disease (biomarker confirmation is mandatory)
- ✗Severe pre-existing interstitial lung disease or pulmonary toxicity
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Uncontrolled severe hypertension or significant bradycardia
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Briganix 180 mg?
Briganix 180 mg is a generic formulation of Brigatinib — a second-generation, reversible dual inhibitor of ALK and EGFR — manufactured by Beacon Pharmaceuticals Ltd., Bangladesh’s largest dedicated oncology manufacturer. Each tablet contains 180 mg of brigatinib, the same active molecule found in Alunbrig® (Takeda), and is dispensed under the Named Patient Program for patients who require an affordable, quality-assured alternative.
Briganix is also available in a 90 mg strength for the mandatory 7-day lead-in period. Both strengths are dispensed in 30-tablet packs.
| Generic name | Brigatinib |
| Reference brand | Alunbrig® (Takeda) |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | ALK / EGFR dual inhibitor (2nd generation) |
| Available strengths | 90 mg and 180 mg tablets |
| Pack size | 30 tablets per pack |
| Route | Oral · once daily |
| Prescription | Required — oncologist only |
How Brigatinib Works
Brigatinib targets the aberrant ALK fusion protein driving tumour cell proliferation in ALK-positive NSCLC. What distinguishes brigatinib is its additional inhibitory activity against EGFR deletions and its potency against a broad range of ALK resistance mutations that develop during first-generation ALK inhibitor therapy.
What to Expect: First 30 Days
Brigatinib has a mandatory lead-in dosing period to reduce the risk of early pulmonary events — understanding this schedule is critical.
- Days 1–7 (90 mg lead-in): You will start at 90 mg once daily. This lower starting dose is clinically mandated to minimise the risk of early-onset pulmonary adverse events (EOPE). Watch for any new breathlessness, cough, or fever and report immediately.
- Day 8 onwards (180 mg): If the 90 mg dose is tolerated without pulmonary events, your oncologist will increase to 180 mg once daily. Common side effects may intensify at this stage.
- Week 4: Blood tests to monitor blood glucose, blood pressure, CPK, and lipase are typically scheduled. Most patients begin to see clinical benefit within the first treatment cycle.
Side Effects
The lead-in dosing period is specifically designed to reduce the most serious early risk — early-onset pulmonary adverse events.
Common · Usually Manageable
- Nausea and diarrhoea
- Fatigue and weakness
- Headache and dizziness
- Elevated blood pressure
- Elevated CPK (muscle enzyme)
- Elevated blood glucose
- Peripheral neuropathy (tingling)
Serious · Report Immediately
- Early-onset pulmonary adverse events (EOPE — within first week)
- Interstitial lung disease / pneumonitis
- Severe hypertension
- Bradycardia
- Severe muscle damage (myopathy)
- New or worsening breathlessness, hypoxia, or cough within the first 7 days (possible EOPE)
- Sudden chest tightness, very slow heart rate, or fainting
- Severe muscle pain with dark-coloured urine (possible rhabdomyolysis)
How to Take Briganix
Mandatory lead-in: 90 mg once daily for 7 days, then increase to 180 mg once daily if tolerated. Do not skip or shorten the lead-in period.
- 1Start at 90 mg for 7 days — take once daily at the same time. After 7 days without pulmonary events, increase to 180 mg as directed.
- 2With or without food — either is acceptable. If nausea is problematic, taking with food typically helps.
- 3Swallow tablets whole — do not crush or split. Take with a full glass of water.
- 4Monitor blood pressure daily — brigatinib causes hypertension in a significant proportion of patients. Keep a daily log.
- 5Storage: below 25°C, protected from moisture and light, out of reach of children.
Caregiver Guidance
- ♥Monitor breathing closely in week 1 — any new cough, breathlessness, or drop in oxygen saturation requires immediate medical contact. Do not wait.
- ♥Check blood pressure twice daily — record and share readings with the care team at every appointment.
- ♥Watch for muscle symptoms — unusual muscle pain, weakness, or dark urine should be reported immediately.
If the Medicine Stops Working
Frequently Asked Questions
Why do I need to start at 90 mg before going to 180 mg?
Can Briganix treat brain metastases from lung cancer?
Who manufactures Briganix and is it reliable?
What is the difference between Briganix 90 mg and 180 mg?
Can I take Briganix if I have diabetes?
How do I order Briganix through Meds For Cancer?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.
This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.
- Camidge DR, et al. Brigatinib versus crizotinib in ALK-positive NSCLC (ALTA-1L). NEJM 2018;379:2027–2039.
- Kim DW, et al. Brigatinib in patients with crizotinib-refractory ALK-positive NSCLC. J Clin Oncol 2017;35:2490–2498.
- NCCN Clinical Practice Guidelines in Oncology: NSCLC. V5.2026.
- Gainor JF, et al. Brigatinib resistance mechanisms in ALK-positive NSCLC. J Thorac Oncol 2021;16:889–899.
Reviews
There are no reviews yet.